Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

[Expression of FOXP1 and cyclinE in primary central nervous system lymphoma and its significance].

Shen L, Chen BB, Chen Z, Xu XP, Lin GW.

Zhonghua Xue Ye Xue Za Zhi. 2012 Aug;33(8):648-52. Chinese.

PMID:
23134861
2.

Prognostic value of clinical characteristics and immunophenotypic biomarkers in 115 patients with primary central nervous system lymphoma.

Chen BB, Xu XP, Shen L, Han TJ, Lin ZG, Chen Z, Kang H, Huang B, Lin GW.

Chin Med J (Engl). 2013 Feb;126(3):482-7.

PMID:
23422111
3.

Preferential expression of truncated isoforms of FOXP1 in primary central nervous system lymphoma.

Courts C, Brunn A, Montesinos-Rongen M, Siemer D, Hans V, Paulus W, Wiestler OD, Küppers R, Siebert R, Deckert M.

J Neuropathol Exp Neurol. 2009 Sep;68(9):972-6. doi: 10.1097/NEN.0b013e3181b31cd6.

PMID:
19680146
4.

Both FOXP1 and p65 expression are adverse risk factors in diffuse large B-cell lymphoma: a retrospective study in China.

Hu CR, Wang JH, Wang R, Sun Q, Chen LB.

Acta Histochem. 2013 Mar;115(2):137-43. doi: 10.1016/j.acthis.2012.06.001. Epub 2012 Jul 17.

PMID:
22809882
5.

FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma.

Yu B, Zhou X, Li B, Xiao X, Yan S, Shi D.

Ann Hematol. 2011 Jun;90(6):701-8. doi: 10.1007/s00277-010-1124-9. Epub 2010 Dec 1.

PMID:
21120478
6.

Primary central nervous system lymphoma: a clinicopathological study of 75 cases.

Preusser M, Woehrer A, Koperek O, Rottenfusser A, Dieckmann K, Gatterbauer B, Roessler K, Slavc I, Jaeger U, Streubel B, Hainfellner JA, Chott A.

Pathology. 2010;42(6):547-52. doi: 10.3109/00313025.2010.508786.

PMID:
20854073
7.

Expression of FOXP1 in mucosa-associated lymphoid tissue lymphoma suggests a large tumor cell transformation and predicts a poorer prognosis in the positive thyroid patients.

Jiang W, Li L, Tang Y, Zhang WY, Liu WP, Li GD.

Med Oncol. 2012 Dec;29(5):3352-9. doi: 10.1007/s12032-012-0288-7. Epub 2012 Jun 27.

PMID:
22736042
8.

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.

Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Enblad G, Leppä S.

Eur J Haematol. 2009 May;82(5):364-72. doi: 10.1111/j.1600-0609.2009.01222.x. Epub 2009 Jan 9.

PMID:
19141121
9.

Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.

Banham AH, Connors JM, Brown PJ, Cordell JL, Ott G, Sreenivasan G, Farinha P, Horsman DE, Gascoyne RD.

Clin Cancer Res. 2005 Feb 1;11(3):1065-72.

10.

Prognostic significance of FOXP1 as an oncogene in hepatocellular carcinoma.

Zhang Y, Zhang S, Wang X, Liu J, Yang L, He S, Chen L, Huang J.

J Clin Pathol. 2012 Jun;65(6):528-33. doi: 10.1136/jclinpath-2011-200547. Epub 2012 Mar 15.

PMID:
22422806
11.

Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.

Sagaert X, de Paepe P, Libbrecht L, Vanhentenrijk V, Verhoef G, Thomas J, Wlodarska I, De Wolf-Peeters C.

J Clin Oncol. 2006 Jun 1;24(16):2490-7. Epub 2006 Apr 24.

PMID:
16636337
12.

Primary central nervous system lymphoma in immunocompetent individuals: a single center experience.

Aki H, Uzunaslan D, Saygin C, Batur S, Tuzuner N, Kafadar A, Ongoren S, Oz B.

Int J Clin Exp Pathol. 2013 May 15;6(6):1068-75. Print 2013.

13.

High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer.

Feng J, Zhang X, Zhu H, Wang X, Ni S, Huang J.

Am J Clin Pathol. 2012 Aug;138(2):230-5. doi: 10.1309/AJCPDHQFNYJZ01YG.

PMID:
22904134
14.

FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.

Hoeller S, Schneider A, Haralambieva E, Dirnhofer S, Tzankov A.

Histopathology. 2010 Jul;57(1):73-80. doi: 10.1111/j.1365-2559.2010.03600.x. Epub 2010 Jun 23.

PMID:
20579129
15.

Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas.

D'Haene N, Catteau X, Maris C, Martin B, Salmon I, Decaestecker C.

Br J Haematol. 2008 Feb;140(4):402-10. Epub 2007 Dec 13.

PMID:
18081894
16.

Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.

Rayoo M, Yan M, Takano EA, Bates GJ, Brown PJ, Banham AH, Fox SB.

J Clin Pathol. 2009 Oct;62(10):896-902. doi: 10.1136/jcp.2009.065169. Epub 2009 Jul 20.

PMID:
19622517
17.

[Prognostic value of cyclin E and its relation to blood vessel invasion in rectal cancer].

Zhou YJ, Wan FL, Yao LH, Feng LY.

Zhonghua Wei Chang Wai Ke Za Zhi. 2008 Mar;11(2):167-71. Chinese.

PMID:
18344087
18.

FOXP1 molecular cytogenetics and protein expression analyses in primary cutaneous large B cell lymphoma, leg-type.

Espinet B, García-Herrera A, Gallardo F, Baró C, Salgado R, Servitje O, Estrach T, Colomo L, Romagosa V, Barranco C, Serrano S, Campo E, Pujol RM, Solé F.

Histol Histopathol. 2011 Feb;26(2):213-21. doi: 10.14670/HH-26.213.

PMID:
21154235
19.

Gene expression signature-based prognostic risk score in patients with primary central nervous system lymphoma.

Kawaguchi A, Iwadate Y, Komohara Y, Sano M, Kajiwara K, Yajima N, Tsuchiya N, Homma J, Aoki H, Kobayashi T, Sakai Y, Hondoh H, Fujii Y, Kakuma T, Yamanaka R.

Clin Cancer Res. 2012 Oct 15;18(20):5672-81. doi: 10.1158/1078-0432.CCR-12-0596. Epub 2012 Aug 20.

20.

Expression of FOXP1 and Colorectal Cancer Prognosis.

De Smedt L, Palmans S, Govaere O, Moisse M, Boeckx B, De Hertogh G, Prenen H, Van Cutsem E, Tejpar S, Tousseyn T, Sagaert X.

Lab Med. 2015 Fall;46(4):299-311. doi: 10.1309/LM7IHV2NJI1PHMXC.

PMID:
26489674

Supplemental Content

Support Center